News

Novo Nordisk Sees Strong Growth Amid R&D Advances

Novo Nordisk Sees Strong Growth Amid R&D Advances

Sales Growth Overview

Novo Nordisk has recently announced a remarkable 12% increase in sales measured in Danish kroner, alongside a substantial 15% rise when factoring in constant exchange rates (CER) during the first nine months of 2025. The company's performance has showcased its resilience and adaptability, positioning it as a leader in the healthcare industry.

Operating Profit and Sales Highlights

The operating profit for Novo Nordisk has climbed by 5% in Danish kroner, reaching DKK 95.9 billion. When looking at constant exchange rates, this figure reflects a 10% increase. Notably, one-time restructuring costs of around DKK 9 billion impacted these figures, but without them, the profit would have surged by 15% in kroner and 21% at CER. This transformation is focused on streamlining operations to reinvest in growth.

US and International Sales Performance

Sales from the US operations saw a 12% growth in kroner, translating to 15% at CER. This growth was buoyed by adjustments in gross-to-net sales. Meanwhile, International Operations demonstrated a healthy growth rate, achieving a 13% increase in kroner and 16% at CER. This showcases the company's strong global market position.

Growth in Diabetes and Obesity Care

Within the segments of Diabetes and Obesity care, sales rose by 12%, totaling DKK 215.7 billion (15% at CER). The growth was heavily influenced by the 37% surge in Obesity care sales, which reached DKK 59.9 billion (41% at CER). Furthermore, sales from GLP-1 diabetes treatments grew by 7% in kroner and 10% at CER, highlighting the demand and effectiveness of these innovative treatments. Additionally, rare disease sales also saw a commendable growth of 10% in kroner and 13% at CER.

Research and Development Progress

Novo Nordisk has made significant strides in its R&D pipeline. The company recently announced the US FDA's approval of an indication for Wegovy for treating MASH conditions. Furthermore, they have plans to acquire Akero Therapeutics, Inc., which promises a robust phase 3 FGF21 analogue for MASH. The company has also submitted Mim8 for regulatory approval within rare blood disorders and initiated the phase 3 development of cagrilintide, potentially the first amylin monotherapy for weight management.

2025 Outlook and Strategic Decisions

Looking ahead, Novo Nordisk anticipates sales growth between 8-11% at CER for the full year, with operating profit growth expected between 4-7%, factoring a negative impact of around DKK 8 billion from their company-wide transformation. The narrowing guidance reflects the changing expectations for the growth of their GLP-1 treatments.

Corporate Developments

In a significant governance move, Novo Nordisk's Board of Directors plans to hold an extraordinary general meeting to elect new members, scheduled for mid-November 2025. Such changes underline the company’s commitment to evolving and adapting its leadership in response to market dynamics.

Mike Doustdar, the president and CEO, shared insights on the operational improvements driven by the company’s transformation. He emphasized the aim to expand treatment options for a larger patient base, especially in obesity management. Doustdar's optimistic view stems from the company's strong sales performance during the year.

About Novo Nordisk

Founded in 1923, Novo Nordisk stands out as a leading global healthcare company headquartered in Denmark. Their mission revolves around defeating serious chronic diseases, particularly diabetes, through pioneering scientific advancements and expanding access to essential medications. With approximately 78,500 employees operating across 80 countries, the company markets its products in around 170 nations. Novo Nordisk's B shares are traded on Nasdaq Copenhagen, while its ADRs are listed on the New York Stock Exchange.

Frequently Asked Questions

What were Novo Nordisk's sales growth rates for 2025?

Sales increased by 12% in Danish kroner and 15% at constant exchange rates for the first nine months of 2025.

What impacted the operating profit of Novo Nordisk?

Operating profit increased by 5% in Danish kroner, impacted by one-off restructuring costs of around DKK 9 billion.

How did the US and International Operations perform?

US operations sales rose by 12% in kroner; International Operations sales grew by 13% in kroner.

What recent R&D developments did Novo Nordisk announce?

Novo Nordisk announced FDA approval for Wegovy in MASH and plans to acquire Akero Therapeutics.

What is the forecast growth for Novo Nordisk in 2025?

The company expects sales growth of 8-11% and operating profit growth of 4-7% for 2025.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 515

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 158

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 65

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading

Top 5 Most Recently Viewed Articles

Ivalua Celebrates Winning Multiple Best Company Awards

Updated Category News Views 104

Ivalua Celebrates Its Recognition with Multiple Best Company Awards Ivalua, a leader in spend management solutions, is excited to share its recent achievements at the Comparably Awards. The company received accolades for Happiest Employees, Best Company Perks & Benefits, and Best Company Work-Life Balance. This recognition underscores Ivalua's commitment to creating an...

Continue Reading
Global Peace Index Reveals Increasing Conflict Trends

Updated Category News Views 371

The 2025 Global Peace Index: A Rising Tide of Conflict The recently released 2025 Global Peace Index (GPI) by the Institute for Economics & Peace (IEP) highlights a troubling trend of declining global peacefulness. The report indicates that we are witnessing a significant change in the global landscape, pointing to a stark reality where conditions leading to conflict are...

Continue Reading
Innovative Device Revolutionizes Painting Techniques and Efficiency

Updated Category News Views 227

Transformative Invention for Painters In the world of painting, efficiency and effectiveness are paramount. Inventors continually seek ways to improve the tools that workers use. One new device, the LOCK & ROLL, aims to enhance the painting experience significantly. Introduction to the LOCK & ROLL This innovative invention is designed to securely anchor paint rollers atop...

Continue Reading
Norfolk Southern's Leadership Crisis: Alan Shaw's Upcoming Exit

Updated Category News Views 130

Norfolk Southern at a Crossroads as Alan Shaw Faces Scrutiny Norfolk Southern Corporation is navigating a tense moment. Chief Executive Alan Shaw is under investigation for alleged ethical violations, including a purported relationship with a company employee. The review has raised questions about leadership, culture, and what accountability should look like at one of the...

Continue Reading
West USA Realty Partners with Zillow to Enhance Listings

Updated Category News Views 235

West USA Realty Embraces Transparency with Zillow West USA Realty, a leading name in the real estate industry, is taking a bold step by aligning with Zillow's standards for consumer access to property listings. This partnership reflects a mutual commitment to transparency and aims to enhance the experience for home buyers and sellers alike. Commitment to Consumers As the...

Continue Reading